ArticleBMC cancer2025
TMEM88 modulates the proliferation and metastasis of HCC via the GSK-3β/β-catenin pathway.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) is one of the most frequent and deadly tumors worldwide. Despite advances in targeted and immunotherapy, its overall survival rates remain low.TMEM88 has drawn a lot of attention for its roles in various cancers; nevertheless, its exact function and mechanisms in HCC are still unknown.
methodsTMEM88 expression was analyzed in 72 HCC tumors vs. adjacent tissues via qPCR/Western blot. Clinical correlations with survival, AFP, and grading were assessed. Functional assays (proliferation, migration, cell cycle) and Wnt/β-catenin signaling (GSK-3β/β-catenin) were evaluated in vitro. Tumor growth was validated in xenografts.
resultsThis study discovered that patients with high TMEM88 expression had significantly improved overall survival and recurrence-free survival, and high expression was associated with lower AFP levels and favorable pathological grading. Furthermore, overexpression of TMEM88 significantly reduced HCC cell proliferation and migration while decreasing the proportion of cells in the S phase of the cell cycle.Western blot analysis revealed that TMEM88 suppresses the Wnt/β-catenin signaling cascade by boosting GSK-3β activity and decreasing β-catenin levels. in vivo tumor xenograft models demonstrated that TMEM88 overexpression substantially inhibited tumor development.
conclusionThis study suggests that TMEM88 may exert tumor-suppressive effects in HCC, potentially through modulation of the GSK-3β/β-catenin pathway, and its higher expression appears to be associated with more favorable outcomes. These findings indicate that TMEM88 could serve as a prognostic biomarker and may have therapeutic relevance, although further validation is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.